A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
about
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
P2860
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A dose escalation feasibility ...... d chronic lymphocytic leukemia
@ast
A dose escalation feasibility ...... d chronic lymphocytic leukemia
@en
type
label
A dose escalation feasibility ...... d chronic lymphocytic leukemia
@ast
A dose escalation feasibility ...... d chronic lymphocytic leukemia
@en
prefLabel
A dose escalation feasibility ...... d chronic lymphocytic leukemia
@ast
A dose escalation feasibility ...... d chronic lymphocytic leukemia
@en
P2093
P2860
P1433
P1476
A dose escalation feasibility ...... d chronic lymphocytic leukemia
@en
P2093
Amy J Johnson
Amy S Ruppert
Cheryl Kefauver
Darlene M Rozewski
Erica Harper
Jeffrey Jones
Joseph Flynn
Kami Maddocks
Leslie A Andritsos
P2860
P304
P356
10.1016/J.LEUKRES.2014.05.011
P50
P577
2014-05-29T00:00:00Z